We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Untitled Letter, sNDA Delay, Amplify Amarin’s Regulatory Woes
FDA Untitled Letter, sNDA Delay, Amplify Amarin’s Regulatory Woes
Amarin has received an FDA untitled letter for omitting risk information in a print promotion for its fish oil drug Vascepa, adding to a pileup of setbacks for the product.